A time to keep and a time to cast away categories of tumor response.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.BMC cancer · 2014
   Trial
2. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.The oncologist · 2021
   Article
3. Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.JCO clinical cancer informatics · 2018
   Article
4. Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.CPT: pharmacometrics & systems pharmacology · 2016
   Article
5. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.Clinical and translational science · 2016
   Article
6. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
   Article
7. Cancer pharmacogenomics: strategies and challenges.Nature reviews. Genetics · 2013
   Review
8. Incorporating biomarkers into clinical trial designs: points to consider.Nature biotechnology · 2012
   Article

Corrections and comments

• Comment on
  Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.2011

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as